Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Barth

Showing results (21-30 of 142) with videos related to

Pageof 15
Sort By:
Cancer Letters|April 7, 2009
Recombinant bispecific single chain antibody fragments induce Fc gamma-receptor-mediated elimination of CD30+ lymphoma cellsKatharina Ranft, Theo Thepen, Rainer Fischer, et al.
Biomacromolecules|January 6, 2023
The Evolution of SNAP-Tag LabelsRudolf Dreyer, Rueben Pfukwa, Stefan Barth, et al.
Current Pharmaceutical Design|February 26, 2013
SNAP-tag technology: a general introductionKatharina Kolberg, Christiane Puettmann, Alessa Pardo, et al.
Cellular & Molecular Immunology|December 22, 2005
Search for "weapons of mass destruction" for cancer -- immuno/ gene therapy comes of ageMing Q Wei, Pat Metharom, Kay A O Ellem, et al.
Antimicrobial Agents and Chemotherapy|October 15, 2014
Antimalarial activity of granzyme B and its targeted delivery by a granzyme B-single-chain Fv fusion proteinStephanie Kapelski, Melanie de Almeida, Rainer Fischer, et al.
Mabs|December 18, 2014
Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapyDmitrij Hristodorov, Radoslav Mladenov, Hannes Brehm, et al.
Protein Expression and Purification|February 12, 2008
Eukaryotic expression and secretion of EGFP-labeled annexin A5Michael Stöcker, Alessa Pardo, Christian Hetzel, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 9, 2008
Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cellsChristian Hetzel, Christopher Bachran, Rainer Fischer, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 25, 2015
Angiogenin mutants as novel effector molecules for the generation of fusion proteins with increased cytotoxic potentialChristian Cremer, Tim Vierbuchen, Lea Hein, et al.
Oncotarget|February 21, 2019
Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cellsNeelakshi Mungra, Sandra Jordaan, Precious Hlongwane, et al.
Pageof 15

Showing results (21-30 of 142) with videos related to

Sort By:
Pageof 15
Cancer Letters|April 7, 2009
Recombinant bispecific single chain antibody fragments induce Fc gamma-receptor-mediated elimination of CD30+ lymphoma cellsKatharina Ranft, Theo Thepen, Rainer Fischer, et al.
Biomacromolecules|January 6, 2023
The Evolution of SNAP-Tag LabelsRudolf Dreyer, Rueben Pfukwa, Stefan Barth, et al.
Current Pharmaceutical Design|February 26, 2013
SNAP-tag technology: a general introductionKatharina Kolberg, Christiane Puettmann, Alessa Pardo, et al.
Cellular & Molecular Immunology|December 22, 2005
Search for "weapons of mass destruction" for cancer -- immuno/ gene therapy comes of ageMing Q Wei, Pat Metharom, Kay A O Ellem, et al.
Antimicrobial Agents and Chemotherapy|October 15, 2014
Antimalarial activity of granzyme B and its targeted delivery by a granzyme B-single-chain Fv fusion proteinStephanie Kapelski, Melanie de Almeida, Rainer Fischer, et al.
Mabs|December 18, 2014
Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapyDmitrij Hristodorov, Radoslav Mladenov, Hannes Brehm, et al.
Protein Expression and Purification|February 12, 2008
Eukaryotic expression and secretion of EGFP-labeled annexin A5Michael Stöcker, Alessa Pardo, Christian Hetzel, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 9, 2008
Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cellsChristian Hetzel, Christopher Bachran, Rainer Fischer, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 25, 2015
Angiogenin mutants as novel effector molecules for the generation of fusion proteins with increased cytotoxic potentialChristian Cremer, Tim Vierbuchen, Lea Hein, et al.
Oncotarget|February 21, 2019
Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cellsNeelakshi Mungra, Sandra Jordaan, Precious Hlongwane, et al.
Pageof 15